Format

Send to

Choose Destination
J Neuropsychiatry Clin Neurosci. 2015;27(2):133-8. doi: 10.1176/appi.neuropsych.13070155.

A trial of d-cycloserine to treat the social deficit in older adolescents and young adults with autism spectrum disorders.

Author information

1
From the Dept. of Psychiatry and Behavioral Sciences, Eastern Virginia Medical School, Norfolk, Virginia (MU, LO, KH, SID); and Virginia Commonwealth University, Richmond, Virginia (PM).

Abstract

Autism spectrum disorders are difficult for older adolescents and young adults as impaired social communication affects the transition to adult life. d-Cycloserine, a partial glycine agonist at the N-methyl-d-aspartic acid receptor, was tested in a double-blind randomized trial in 20 older adolescents and young adults with autism spectrum disorders using two dosing strategies (50 mg daily versus 50 mg weekly) for 8 weeks with a 2-week follow-up after discontinuation. d-Cycloserine caused statistically and clinically significant improvement with no differentiation between dosing strategies on the Social Responsiveness Scale and the Aberrant Behavior Checklist before and after d-cycloserine administration.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center